Bio-Techne Targets 100 Basis Points Margin Growth in FY26 After Exosome Divestiture

Key Highlights from Bio-Techne’s Q4 2025 Earnings Call

Bio-Techne Corporation (TECH) delivered a solid performance in the fourth quarter of 2025, with several key highlights that reflect both strengths and challenges in the company’s operations. The CEO, Kim Kelderman, emphasized the company's ability to meet expectations, citing 3% organic revenue growth driven by strong demand for automated proteomic analytical instrumentation and cell therapy solutions. This demand came primarily from large pharmaceutical companies, which continue to be a critical driver for the business.

Kelderman also highlighted the decision to divest the Exosome Diagnostics business, a move that was part of a broader strategic evaluation. He explained that the business, while profitable, did not offer enough operational leverage to support the company’s long-term growth goals. The sale is expected to contribute positively to the company’s already strong operating margin profile.

The CFO, James T. Hippel, reported that adjusted earnings per share (EPS) for the quarter reached $0.53, up from $0.49 in the same period last year. Revenue totaled $317 million, reflecting a 3% increase on an organic basis and 4% when including all factors. Additionally, the company returned capital to shareholders through dividends and stock buybacks, totaling $112.5 million.

Outlook and Strategic Shifts

Looking ahead, management expects organic growth to remain in the low single-digit range until current market headwinds ease. However, they anticipate an adjusted operating margin expansion of approximately 100 basis points in fiscal year 2026 compared to fiscal 2025. This improvement is expected to start flat in the first quarter but accelerate toward the end of the year, with a projected increase of around 200 basis points by the fourth quarter.

Investments previously allocated to the ExoDx franchise will now be redirected toward core growth areas such as proteomic analysis, spatial biology, and cell therapy applications. This shift underscores the company’s focus on long-term value creation and strategic alignment with high-growth opportunities.

Financial Performance and Segment Analysis

In terms of financial results, the company generated $98.2 million in cash from operations during the quarter. Adjusted gross margin for the quarter was 70.1%, down slightly from 71.1% in the prior year. Adjusted operating margin for Q4 stood at 32%, a decrease of 150 basis points compared to the previous year, largely due to an unfavorable product mix.

The Protein Sciences segment reported sales of $226.5 million, with 4% organic growth and an operating margin of 43.6%. The Diagnostics and Spatial Biology segment saw sales of $89.7 million, with both reported and organic growth declining by 1% and an operating margin of 6%.

Analyst Questions and Market Sentiment

During the Q&A session, analysts raised several concerns about the company’s guidance, margin expansion, and the impact of macroeconomic uncertainties. There was a general sense of caution among analysts, with many pressing for more clarity on growth drivers and mitigation strategies.

Management maintained a neutral to slightly positive tone in their prepared remarks, emphasizing operational discipline and portfolio resilience. However, during the Q&A, the tone shifted to a more cautious stance, with executives using phrases like “we expect” and “we believe,” while deferring specifics due to ongoing uncertainty.

Compared to the previous quarter, both analysts and management expressed greater concern about persistent uncertainties, particularly regarding NIH funding and potential tariff impacts. This has led to increased scrutiny of the company’s financial outlook and strategic direction.

Quarterly Comparison and Risk Factors

Organic revenue growth slowed from 6% in Q3 to 3% in Q4, and adjusted operating margin declined from 34.9% to 32%. The Q4 call marked a significant strategic shift, with the Exosome Diagnostics divestiture positioning the company for future margin expansion.

Analysts have shifted their focus from previous concerns about tariffs and academic market headwinds to more immediate issues such as margin sustainability, the pace of growth recovery, and the impact of the Exosome sale. Management’s tone in Q4 was more cautious than in Q3, with less certainty about the timing of market stabilization.

Risks and Mitigation Strategies

Key risks cited by management include U.S. pharmaceutical tariffs, potential changes in NIH funding, and constrained biotech funding. The CFO warned of emerging risks, including budget precision and a possible shift toward multi-year grant funding by the executive branch.

To mitigate these challenges, the company is focusing on cost containment, operational efficiencies, and redirecting investments into core growth areas. These strategies are aimed at maintaining financial stability and supporting long-term growth despite external headwinds.

Final Thoughts

Bio-Techne’s Q4 2025 earnings call demonstrated the company’s resilience in navigating macroeconomic uncertainties. With stable performance in key end markets and a strategic divestiture poised to drive margin expansion, the company is well-positioned to create long-term value. By balancing investment in growth pillars with cost controls, Bio-Techne is preparing for a return to higher growth once market conditions stabilize.